Low Disease Activity

Low disease activity and remission definitions used for adult systemic lupus erythematosus are achievable among children and can significantly reduce the risk for severe flare, according to data published in Rheumatology.

In an extension of the REDO trial, most patients with rheumatoid arthritis on ultra-low-dose rituximab — either 200 or 500 mg — maintained low disease activity for up to 4 years, according to data presented at ACR Convergence 2021.

Some patients with rheumatoid arthritis still demonstrate residual symptoms despite achieving low-disease activity or remission, according to findings published in Arthritis Care & Research.